Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome
نویسندگان
چکیده
INTRODUCTION Acute heart failure syndrome (AHFS) is one of the leading causes of hospital admission in the US. Tolvaptan is a vasopressin V(2) receptor antagonist that blocks the effect of arginine vasopressin (AVP) in reabsorbing water from the collecting ducts of the nephrons in congestive heart failure. AIMS To review the evidence for utilizing tolvaptan in the treatment of AHFS. EVIDENCE REVIEW Several clinical trials have sought to assess the clinical effects of tolvaptan in heart failure. Compared with placebo, tolvaptan has been shown to reduce bodyweight and improve serum sodium in patients with AHFS without worsening renal function. Tolvaptan appeared to be well tolerated with a good safety profile. It caused a significant reduction in pulmonary capillary wedge pressure compared with placebo, but has yet to demonstrate reversal of cardiac remodeling. A large-scale mortality trial showed no differences in long-term mortality rates between tolvaptan and placebo, although early symptom relief was apparent with tolvaptan and lower diuretic use. PLACE IN THERAPY Tolvaptan has shown to be safe and effective in treating congestion in AHFS. Free water excretion in fluid-overloaded patients vulnerable to cardiorenal compromise with standard diuretic therapy makes V(2) vasopressin receptor blockade an attractive adjunct to standard medical therapy aimed at reducing congestion in AHFS.
منابع مشابه
Tolvaptan: A Novel Diuretic in Heart Failure Management
Heart failure (HF) is still a major problem worldwide with high morbidity and mortality rates. The recently developed medication for HF is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient. Arginine-vasopressin (AVP) plays important roles in circulatory and water homeostasis, one of which is ...
متن کاملTolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration
متن کامل
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure Mihai Gheorghiade, MD, Wendy A. Gattis, PharmD, Alejandro Barbagelata, MD, Kirkwood F. Adams, Jr, MD, Uri Elkayam, MD, Cesare Orlandi, MD, and Christopher M. O’Connor, MD, for the Acute and Chronic Therapeutic Impact of...
متن کاملArginine Vasopressin Receptor Antagonists for Heart Failure
eart failure (HF) is among the most common causes of ospitalization, and its incidence will likely increase in an ging population of “survivors” (1). Pharmacological treatent targeted at neurohormonal activation has improved urvival, but mortality remains substantial in patients with F, thus warranting the search for novel therapeutic aproaches. Novel agents under investigation for the treatent...
متن کاملTolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
Congestion is a primary reason for hospitalization in patients with acute heart failure (AHF). Despite inpatient diuretics and vasodilators targeting decongestion, persistent congestion is present in many AHF patients at discharge and more severe congestion is associated with increased morbidity and mortality. Moreover, hospitalized AHF patients may have renal insufficiency, hyponatremia, or an...
متن کامل